logo

For the Inventor, By the Inventor

Cranbury, NJ, United States of America

Palatin Technologies Incorporated


USPTO Granted Patents = 68

% Expired Patents = 30.9



Trademarks = 4

Forward Citations = 435

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal Shubh D Sharma (47 out of 62 patents)

silverMedal Yi-Qun Shi (36 out of 36 patents)

bronzeMedal Wei Yang (32 out of 32 patents)

4.  Ramesh Rajpurohit (19 out of 19 patents)

5.  Annette M Shadiack (14 out of 19 patents)

6.  Zhijun Wu (13 out of 13 patents)

7.  Kevin D Burris (10 out of 10 patents)

8.  Margarita Bastos (9 out of 14 patents)

9.  Hui-Zhi Cai (9 out of 9 patents)

10.  John H Dodd (8 out of 9 patents)

11.  Papireddy Purma (7 out of 7 patents)

12.  Carl Spana (5 out of 5 patents)

13.  Xin Chen (5 out of 5 patents)

14.  Jeffrey D Edelson (4 out of 4 patents)

15.  Yadi Reddy Bonuga (4 out of 4 patents)


Core Competencies:
Melanocortin-1 Receptor
Bremelanotide
Peptide Constructs
Cyclic Peptides
Obesity Therapy
Inflammation Treatment
Sexual Dysfunction
Peptidomimetics
Natriuretic Peptides
Piperazine Compounds
Metallopeptides
Cachexia Treatment

68 patents:

1. 12692291 - Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications (2026-07-28),
2. 12459894 - Orally active melanocortin receptor-4 compounds (2025-11-04),
3. 11590209 - Use of bremelanotide in patients with controlled hypertension (2023-02-28),
4. 11286280 - Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy (2022-03-29),
5. 10711039 - Melanocortin receptor-specific peptide with C-terminal naphthylalanine (2020-07-14),
6. 10660939 - Therapies for obesity, diabetes and related indications (2020-05-26),
7. 10632171 - Melanocortin receptor-specific peptides (2020-04-28),
8. 10286034 - Uses of bremelanotide in therapy for female sexual dysfunction (2019-05-14),
9. 10179804 - Melanocortin receptor-specific peptides (2019-01-15),
10. 10106578 - Melanocortin-1 receptor-specific linear peptides (2018-10-23),
11. 10017539 - Melanocortin-1 receptor-specific cyclic hexapeptides (2018-07-10),
12. 9700592 - Uses of bremelanotide in therapy for female sexual dysfunction (2017-07-11),
13. 9580466 - Melanocortin-1 receptor-specific linear peptides (2017-02-28),
14. 9458201 - Melanocortin receptor-specific heptapeptides (2016-10-04),
15. 9447148 - Melanocortin-1 receptor-specific cyclic peptides (2016-09-20),
Palatin Technologies Incorporated, based in Cranbury, NJ, specializes in the development of innovative therapeutics targeting melanocortin receptors. The company focuses on peptide constructs and cyclic peptides, with applications in obesity therapy, inflammation treatment, and sexual dysfunction. Notably, Palatin is known for its work on Bremelanotide, a novel treatment aimed at addressing sexual dysfunction. Through its research, Palatin aims to advance the understanding and therapeutic potential of peptidomimetics in various medical conditions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Palatin Technologies Incorporated
68 Patents

#3 in Cranbury, NJ

#228 in New Jersey

#5,369 in US

#10,880 in the World

Cranbury, NJ (US)
Cranbury, NJ, United States of America

Palatin Technologies Incorporated

Forward Citations = 435

31 inventors:

goldMedal Shubh D Sharma (47 out of 62 patents)

silverMedal Yi-Qun Shi (36 out of 36 patents)

bronzeMedal Wei Yang (32 out of 32 patents)

4.  Ramesh Rajpurohit (19 out of 19 patents)

5.  Annette M Shadiack (14 out of 19 patents)

Please report any incorrect information to [email protected]
Loading…